## Abstract HeLa cells grown in chemically defined medium lacking glucocorticoids synthesize metallothioneins, low molecular‐weight heavy‐metal binding proteins. Dexamethasone and hydrocortisone increase the rate of metal‐lothionein synthesis five‐ to ten‐fold. Maximal induction is achieved with 10
Glucocorticoid induction of proline oxidase in LLC-RK1 cells
✍ Scribed by Edward M. Kowaloff; Dr. James M. Phang; Alnora S. Granger; Sylvia J. Downing
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- English
- Weight
- 508 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Dexamethasone induced proline oxidase in cultured LLC‐RK1 cells, an epithelial cell line derived from rabbit kidney. The dexamethasone‐mediated increase in enzyme activity was concentration and time dependent. Although the effect could be dissociated from cell growth and cell density, it was dependent on protein and RNA synthesis. A comparison of the enzyme isolated from control and dexamethasone‐treated cells showed that the increased activity was not due to an alteration in the affinity of the enzyme for proline. These findings suggest that glucocorticoids induce the synthesis of proline oxidase in mammalian cells.
📜 SIMILAR VOLUMES
## Abstract Several clones of dexamethasone‐resistant cells, which could not differentiate even in a high concentration of dexamethasone, were isolated from glucocorticoid‐sensitive myeloid leukemic cells. Some of them were shown to be deficient in steroid binding to specific cytoplasmic receptors,
## BACKGROUND. Previously, the authors reported that specific antisense suppression of overexpressed proline-directed protein kinase (PDPK) F A enhances the chemosensitivity of various clinical anticancer drugs up to Ͼ 100-fold in human prostate carcinoma cells, suggesting an association of PDPK F
## Abstract The ErbB family of receptor kinases is composed of four members: epidermal growth factor receptor (EGFR/ErbB1), ErbB2/neu, ErbB3, and ErbB4. Amplification of the ErbB2/neu is found in about 30% of breast cancer patients and is associated with a poor prognosis. Heregulin (HRG) activates